Ceftriaxone Injection 2 grams (Ceftriaxone Sodium Hydrate)

Adult administration

For adults and children over 12 years: administer 1-2 g (as potency) of ceftriaxone once a day by intravenous or intramuscular injection. In cases of severe disease or infections due to moderately susceptible pathogens, the dose may be increased to 4 g (as potency) once a day. For infection prophylaxis before and after surgery, a single dose of 1-2 g (as potency) should be given 30-90 minutes before surgery. In cases of renal and liver dysfunction, if creatinine clearance is 1 mL/min or less, do not exceed 2 g (as potency) per day.

Child administration

For neonates (up to 14 days old), administer 20-50 mg (as potency) per kg of body weight once a day, not exceeding 50 mg (as potency). No distinction is made between premature and term infants. For infants and children (from 15 days to 12 years)

This medication should not be mixed or administered simultaneously with calcium-containing solutions or other medications. It is prohibited for administration to neonates due to the risk of precipitation when calcium interacts with this drug. In neonates receiving this medication and calcium together, there may be severe issues from precipitation in the lungs and kidneys. It should not be used in patients with hypersensitivity to this medication or allergic to cephalosporins or penicillins. The product containing lidocaine must not be administered intravenously. Do not administer this medication to premature infants or neonates suspected of having bilirubin binding disorders. During administration, careful observation for allergic reactions, renal dysfunction, liver dysfunction, etc., is essential. If severe allergic reactions occur, discontinue immediately and seek emergency treatment. This medication may cause various side effects including gastrointestinal disorders, skin rashes, blood abnormalities, and neurological issues; thus, any symptoms should be reported to the healthcare provider. It is crucial to regularly check liver and kidney function and blood tests during administration. This medication should be administered cautiously to pregnant or nursing women, as safety for the fetus or neonate has not been fully established. Elderly patients may experience more side effects due to decreased bodily functions, thus adjustment of dosage and frequency is necessary. Be attentive to potential influences on clinical test results, such as blood glucose or urine glucose tests, when using this medication. When administering, ensure that the medication is injected quickly into the vein, and pay attention to injection techniques to prevent adverse reactions at the injection site. In case of overdose, as there is no specific antidote, symptomatic treatment is required. Caution is advised when driving or operating machinery, as dizziness or other side effects may occur. This medication and calcium-containing solutions should not be administered through the same injection port, and thorough washing of the infusion line is necessary between administrations. Careful administration is required when used in conjunction with other medications to consider possible interactions.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, rash, anaphylaxis or anaphylactoid reaction, severe skin adverse reactions (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), acute generalized exanthematous pustulosis (AGEP), liver abnormalities (jaundice), encephalopathy, seizures, altered consciousness, neurological symptoms, markedly reduced urine output, severe edema with elevated blood pressure, shock, pulmonary and renal issues

Mild side effects

Eosinophilia, leukopenia, thrombocytopenia, diarrhea, rash, increased liver enzymes, headache, dizziness, bronchospasm, loose stools, nausea, vomiting, itching, hematuria, diabetes, phlebitis, injection site pain, fever, swelling, chills, increased serum creatinine, pseudomembranous colitis, agranulocytosis, anemia, coagulation disorders, gastrointestinal symptoms (abdominal pain, loss of appetite, abdominal distension, indigestion), pancreatitis, dysbiosis, stomatitis, candidiasis,

This medication should be stored in a sealed container to prevent contact with air and kept at a temperature between 1 to 30 degrees Celsius. This storage method helps maintain the efficacy of the medication for a longer period.

Appearance

Type I (Vial): A colorless transparent vial filled with white or pale yellow powder Type II (Mapset kit): An accompanying saline injection solution for dilution and a transfer device

Package unit

Type I - 10 vials/box [1 vial x 10], Type II - 10 kits/box [1 kit x 10]